Physicians' Academy for Cardiovascular Education

New cholesterol guidelines help identify patients at highest risk who will benefit most from treatment

3' education - Nov. 11, 2018

LDL lowering versus LDL eradication; what makes clinical sense ?

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands

Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Jennifer Robinson, MD - Iowa city, Iowa, USA

PCSK9 inhibitors may represent the first therapeutic means to lower Lp(a)

3' education - June 29, 2018 - John Chapman - Paris, France

Laboratory investigation of lipids and lipoproteins

10' education - Aug. 21, 2018 - Prof. David Marais - Cape Town, South Africa

Advancing insights into Lp(a) as a causal factor in CVD

3' education - June 29, 2018 - John Chapman - Paris, France

Dietary lipids in perspective

10' education - July 10, 2018 - Prof. David Marais - Cape Town, South Africa

Greater absolute benefit with PCSK9 inhibition in diabetes patients

3' education - July 3, 2018 - Prof. Kausik Ray, Imperial College London, UK

Estimating CV risk and treatment benefit

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands - Online CME
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (1/3)

The cardiovascular challenge for primary care in diabetes

10' education - June 14, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME

Familial dysbetalipoproteinemia: Pathofysiology, diagnosis and treatment

10' education - Apr. 11, 2018 - Charlotte Koopal - Utrecht, The Netherlands

The role of lipids in CVD prevention: Lessons learned about statins

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands - Online CME

Familial hypercholesterolemia: Diagnosis and management

10' education - Apr. 10, 2018 - Prof. Frederick Raal - Johannesburg, South Africa

Emerging approaches to dyslipidemia management beyond LDL-c

3' education - Mar. 9, 2018 - VBWG at ACC 2018, Orlando, FL, USA - Eliot Brinton, Salt Lake City, UT, USA

Statin-associated muscle symptoms: real or nocebo effect?

3' education - Mar. 9, 2018 - VBWG at ACC 2018, Orlando, FL, USA - Prof. Paul Thompson, Hartford, CT, USA

Dyslipidemia in diabetes patients

10' education - Apr. 10, 2018 - Prof. Kausik Ray - Imperial College London, UK
Also as CME accredited e-learning

The CANTOS trial: Implications for the management of patients with residual risk

10' education - Nov. 16, 2017 - Prof. Paul Ridker - Boston, MA, USA - Online CME

Anti-inflammatory therapy in the prevention of cardiovascular disease

10' education - Nov. 16, 2017 - Prof. Peter Libby, USA

Results ODYSSEY OUTCOMES study can change clinical practice for treatment of high-risk ACS patients

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA

Very good benefit-to-risk profile with PCSK9 inhibitor in high risk ACS patients in ODYSSEY OUTCOMES trial

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Prof. Gabriel Steg, Paris, France
Also as CME e-learning

Inflammation & CVD: Translating insights from vascular biology to the clinic

10' education - Nov. 16, 2017 - Prof. Peter Libby, USA - Online CME
Also as CME accredited e-learning

The new era of residual risk reduction

10' education - Nov. 16, 2017 - Prof. Erik Stroes - Amsterdam, The Netherlands - Online CME

The patient with inflammatory residual risk: Who is it?

10' education - Nov. 16, 2017 - Prof. Wolfgang Koenig - Munich, Germany - Online CME

Diabetic dyslipidemia and residual risk in the era of LDL control

10' education - Jan. 25, 2018 - Boston, MA, USA - Dr. Aruna Pradhan - Brigham & Women's Hospital, Boston, USA

Lipoprotein metabolism & CV risk: a long road from understanding to treatment

10' education - Jan. 6, 2017 - Prof. John JP Kastelein, Amsterdam, The Netherlands

REVEALing where we stand with HDL

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Christopher Cannon - Brigham & Women's Hospital, Boston, USA

Lipid management in primary prevention: Challenges in the era of low LDL-c & novel therapies

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Samia Mora - Brigham & Women's Hospital, Boston, MA, USA

Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

10' education - Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA

Can LDL go too low? Lessons from 25 years of cholesterol lowering

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Robert Giugliano - Brigham & Women's Hospital, Boston, USA

More insight into effects of treatment with PCSK9 inhibition from 5 new FOURIER analyses

3' education - Nov. 14, 2017 - Anaheim, CA, USA - Robert Giugliano - Boston, MA, USA

Reduced all-cause mortality with PCSK9 inhibitor in patients with ACS

AHA 2018 – Chicago, IL, VS

News - Nov. 12, 2018

AHA 2018 Post-hoc analyses of the ODYSSEY OUTCOMES trial showed reduced all-cause mortality with alirocumab vs statins in patients with ACS, especially in those with LDL-c of ≥100 mg/dL at baseline.

Cholesterol absorption inhibitor prevents atherosclerotic CV events in older patients

AHA 2018 – Chicago, IL, USA

News - Nov. 12, 2018

AHA 2018 In Japanese patients aged ≥75 years with elevated LDL-c levels, ezetimibe results in prevention of atherosclerotic CV events, as shown in the EWTOPIA75 randomized trial.

2018 Guidelines on the management of cholesterol: take home messages

News - Nov. 11, 2018

AHA 2018 The American Heart Association (AHA) and the American College of Cardiology (ACC) updated the 2018 cholesterol guidelines. A summary of key recommendations concerning cholesterol management in de prevention of CVD.

Apo(a) antisense oligonucleotides safely and effectively reduces Lp(a) in patients with CVD

AHA 2018 – Chicago, IL, USA

News - Nov. 11, 2018

AHA 2018 A randomized phase 2b trial showed safety and efficacy of the antisense nucleotide AKCEA-APO(a)-Lrx at reducing Lp(a) levels in patients with CVD.

New cholesterol guidelines help identify patients at highest risk who will benefit most from treatment

AHA 2018 - Chicago, IL, USA

3' education - Nov. 11, 2018
Neil Stone served as vice-president of the new cholesterol guideline. He sums up the main new recommendations based on the latest evidence of recent lipid outcome trials.

AHA 2018 Neil Stone served as vice-president of the new cholesterol guideline. He sums up the main new recommendations based on the latest evidence of recent lipid outcome trials.

Updated AHA/ACC cholesterol guidelines focus on more personalized risk assessment

AHA 2018 – Chicago, IL, USA

News - Nov. 11, 2018
The updated cholesterol guidelines help physicians to personalize treatment based on risk assessment, and now include CAC measurement to guide treatment decisions in certain patients.

AHA 2018 The updated cholesterol guidelines help physicians to personalize treatment based on risk assessment, and now include CAC measurement to guide treatment decisions in certain patients.

Meeting Impression | PCSK9 inhibition: Science, outcomes & guidance

August 25, 2018 - Munich, Germany
August 25, 2018 - Munich, Germany

Download the meeting impression of this PACE symposium during ESC 2018, which reviewed PCSK9 inhibition with regard to science, outcomes and guidance.

PCSK9-antibodies do not significantly affect balance cholesterol synthesis and absorption

Literature - Oct. 17, 2018 - Silbernagel G et al. - J Lipid Res 2018

PCSK9-antibodies reduce non-cholesterol sterols but they do not significantly affect the balance between cholesterol synthesis and absorption, irrespective of cholesterol-lowering pretreatment.

U-Prevent helps predict individual effect of medication on CVD

News - Oct. 16, 2018

The UMC Utrecht's Center for Circulatory Health has developed algorithms with which the risk of CVD and the effect of medication to reduce this risk, can be predicted for every adult. Use of the risk calculators is free.

LDL lowering versus LDL eradication; what makes clinical sense ?

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands
Prof. Kastelein discusses whether LDL-c eradication makes more sense than LDL-c lowering, based on the latest scientific insights.

Prof. Kastelein discusses whether LDL-c eradication makes more sense than LDL-c lowering, based on the latest scientific insights.

Summary | Translating GLP-1 trial outcomes to cardiology practice: Which patients will benefit?

August 27, 2018 – Lars Rydén, MD

This is a summary of the presentation by Lars Rydén, in which he presents which patients will likely benefit from GLP-1RA therapy by discussing differences observed between GLP-1RA trials.

Low hs-CRP associated with lower risk of adverse outcomes in primary prevention cohort

Literature - Sep. 25, 2018 - Penson PE et al. - Eur Heart J 2018

In the REGARDS cohort, low hs-CRP levels were associated with a reduced risk of stroke, and CHD morbidity and mortality, while low LDL-c was not associated with protective effects.